These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17207956)

  • 61. Desmoplastic melanoma: a 12-year experience with sentinel lymph node biopsy.
    Broer PN; Walker ME; Goldberg C; Buonocore S; Braddock DT; Lazova R; Narayan D; Ariyan S
    Eur J Surg Oncol; 2013 Jul; 39(7):681-5. PubMed ID: 23522951
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study.
    Mozzillo N; Pasquali S; Santinami M; Testori A; Di Marzo M; Crispo A; Patuzzo R; Verrecchia F; Botti G; Montella M; Rossi CR; Caracò C
    Eur J Surg Oncol; 2015 Jul; 41(7):823-9. PubMed ID: 25800935
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Whole-body 18 FDG PET/CT imaging for lymph node and metastatic staging of conjunctival melanoma.
    Kurli M; Chin K; Finger PT
    Br J Ophthalmol; 2008 Apr; 92(4):479-82. PubMed ID: 18369064
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sentinel lymph node detection in thyroid carcinoma using
    de Vries LH; Lodewijk L; de Keizer B; Borel Rinkes IH; Vriens MR
    Future Oncol; 2022 Oct; 18(31):3493-3499. PubMed ID: 36069284
    [TBL] [Abstract][Full Text] [Related]  

  • 65. PET-CT for staging pT4b melanomas prior to sentinel lymph node biopsy: a 5-year review.
    Hardie CM; Allouni A; Edwards S; Ahmed N; Maraveyas A; Matteucci PL
    Melanoma Res; 2021 Aug; 31(4):397-401. PubMed ID: 34039943
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Utility of PET/CT in patients with stage I-III melanoma.
    Avilés Izquierdo JA; Molina López I; Sobrini Morillo P; Márquez Rodas I; Mercader Cidoncha E
    Clin Transl Oncol; 2020 Aug; 22(8):1414-1417. PubMed ID: 31873917
    [TBL] [Abstract][Full Text] [Related]  

  • 67. FDG PET in early stage cutaneous malignant melanoma.
    McIvor J; Siew T; Campbell A; McCarthy M
    J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Initial staging of malignant melanoma by positron emission tomography and sentinel node biopsy.
    Libberecht K; Husada G; Peeters T; Michiels P; Gys T; Molderez C
    Acta Chir Belg; 2005; 105(6):621-5. PubMed ID: 16438072
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of positron emission tomography and computed tomography in clinical staging of cutaneous malignant melanoma.
    Yılmaz H; Orhan E; Şahin E; Olguner AA; Arpacı E
    Dermatol Ther; 2020 May; 33(3):e13304. PubMed ID: 32160381
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PET-CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapy.
    Mor E; Schtrechman G; Nizri E; Shimonovitz M; Asher N; Ben-Betzalel G; Grynberg S; Stoff R; Miodovnik M; Adileh M; Ben-Yaacov A; Steinberg Y; Shapira R; Schachter J; Lahat G; Nissan A; Zippel D; Laks S
    Eur J Surg Oncol; 2023 Oct; 49(10):106950. PubMed ID: 37301639
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma.
    Wagner JD; Schauwecker D; Hutchins G; Coleman JJ
    J Surg Oncol; 1997 Mar; 64(3):181-9. PubMed ID: 9121147
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Use of Preoperative PET/CT Staging in Sentinel Lymph Node-Positive Melanoma.
    Scheier BY; Lao CD; Kidwell KM; Redman BG
    JAMA Oncol; 2016 Jan; 2(1):136-7. PubMed ID: 26401901
    [No Abstract]   [Full Text] [Related]  

  • 73. Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients.
    Singh N; Alexander NA; Lachance K; Lewis CW; McEvoy A; Akaike G; Byrd D; Behnia S; Bhatia S; Paulson KG; Nghiem P
    J Am Acad Dermatol; 2021 Feb; 84(2):330-339. PubMed ID: 32707254
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Patients with cutaneous head and neck melanoma, particularly elderly with more advanced primary tumors, seem to benefit from initial CT staging before considering a sentinel lymph node biopsy.
    Hafström A; Nateghi-Gillberg B; Nilsson MA; Greiff L
    Acta Otolaryngol; 2020 Sep; 140(9):795-802. PubMed ID: 32522134
    [No Abstract]   [Full Text] [Related]  

  • 75. Selection of patients with malignant melanoma for pelvic lymph node dissection (PLND) using CT-PET.
    Ali T; Powell R; Short J; Scatchard K; Stone C
    J Plast Reconstr Aesthet Surg; 2024 Feb; 89():30-32. PubMed ID: 38128371
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Positron emission tomography/computed tomography in melanoma.
    Bourgeois AC; Chang TT; Fish LM; Bradley YC
    Radiol Clin North Am; 2013 Sep; 51(5):865-79. PubMed ID: 24010910
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Advancements in the diagnosis of melanoma].
    Liszkay G
    Magy Onkol; 2015 Mar; 59(1):68-72. PubMed ID: 25763916
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Validation of statistical predictive models meant to select melanoma patients for sentinel lymph node biopsy.
    Sabel MS; Rice JD; Griffith KA; Lowe L; Wong SL; Chang AE; Johnson TM; Taylor JM
    Ann Surg Oncol; 2012 Jan; 19(1):287-93. PubMed ID: 21822550
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Regional lymph node assessment for conjunctival melanoma: sentinel lymph node biopsy and positron emission tomography.
    Esmaeli B
    Br J Ophthalmol; 2008 Apr; 92(4):443-5. PubMed ID: 18369054
    [No Abstract]   [Full Text] [Related]  

  • 80. Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients.
    Vereecken P; Laporte M; Petein M; Steels E; Heenen M
    J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):66-73. PubMed ID: 15649194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.